BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 18194706)

  • 21. Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients.
    Kaul S; Savera A; Badani K; Fumo M; Bhandari A; Menon M
    BJU Int; 2006 Mar; 97(3):467-72. PubMed ID: 16469009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological presence of viable prostatic glands on routine biopsy following cryosurgical ablation of the prostate.
    Shuman BA; Cohen JK; Miller RJ; Rooker GM; Olson PR
    J Urol; 1997 Feb; 157(2):552-5. PubMed ID: 8996354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
    BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
    Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
    BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results.
    Maestroni U; Ziveri M; Azzolini N; Dinale F; Ziglioli F; Campaniello G; Frattini A; Ferretti S
    Acta Biomed; 2008 Dec; 79(3):211-6. PubMed ID: 19260381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes.
    El Hayek OR; Alfer W; Reggio E; Pompeo AC; Arap S; Lucon AM; Srougi M
    Urol Int; 2008; 81(2):186-90. PubMed ID: 18758217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
    Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
    J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience.
    Woodrum DA; Kawashima A; Karnes RJ; Davis BJ; Frank I; Engen DE; Gorny KR; Felmlee JP; Callstrom MR; Mynderse LA
    Urology; 2013 Oct; 82(4):870-5. PubMed ID: 23910089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
    Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
    Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
    Dhar N; Ward JF; Cher ML; Jones JS
    BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
    BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
    Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
    Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer.
    Muto S; Yoshii T; Saito K; Kamiyama Y; Ide H; Horie S
    Jpn J Clin Oncol; 2008 Mar; 38(3):192-9. PubMed ID: 18281309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.
    Murat FJ; Poissonnier L; Rabilloud M; Belot A; Bouvier R; Rouviere O; Chapelon JY; Gelet A
    Eur Urol; 2009 Mar; 55(3):640-7. PubMed ID: 18508188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.